title: Effect of the slow-release formulation of somatuline (BIM 23014) on estrogen-induced hyperprolactinemia and lactotroph hyperplasia in the female rat.
abstract: Somatuline, in common with other SRIH analogues, exerts antiproliferative and antisecretory activities on various tumors. Our purpose was to test the effectiveness of a slow-release formulation of somatuline on lactotroph hyperplasia and PRL hypersecretion induced by estrogens (17 beta E2) in rats. Female rats were primed with 17 beta E2 for 6 weeks before receiving somatuline (2 mg/kg) intramuscular injections every 10 days for one month. The mean anterior pituitary weight was 11.22 +/- 0.32 mg (mean +/- SEM) in non-estrogenized rats, 29.62 +/- 1.63 mg in 17 beta E2-primed rats and 23.58 +/- 1.26 mg in 17 beta E2-primed somatuline-treated rats. Mean plasma PRL level was 5.63 +/- 0.97 ng/ml, 182.37 +/- 27.55 ng/ml and 113.89 +/- 15.07 ng/ml in the same groups respectively. Thus, the 17 beta E2-induced pituitary enlargement and hyperprolactinemia were 20% and 38% lower respectively when animals were treated with somatuline during the last month of estrogenization. The 17 beta E2-induced increase in PRL cell density was also reduced by somatuline treatment. We conclude that the slow-release formulation of somatuline impedes 17 beta E2-induced hyperprolactinemia and pituitary enlargement concomittantly, at least in part by acting on lactotroph proliferation.
authors.affiliation: Unité INSERM 223, Faculté de Médecine Pitié-Salpêtrière, Paris, France.
authors.forename: N
authors.initials: N
authors.lastname: Schussler
authors.forename: R
authors.initials: R
authors.lastname: Farnoud
authors.forename: C
authors.initials: C
authors.lastname: Rauch
authors.forename: M
authors.initials: M
authors.lastname: Roche
authors.forename: M
authors.initials: M
authors.lastname: Berthet
authors.forename: F
authors.initials: F
authors.lastname: Thomas
authors.forename: F
authors.initials: F
authors.lastname: Peillon
authors.forename: M C
authors.initials: MC
authors.lastname: Bayet
mesh_terms: D000818:Animals; D003692:Delayed-Action Preparations; D004334:Drug Administration Schedule; D004347:Drug Interactions; D004958:Estradiol / Q000494:pharmacology*; D005260:Female; D007273:Injections, Intramuscular; D015282:Octreotide / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D009929:Organ Size; D010456:Peptides, Cyclic; D010903:Pituitary Gland, Anterior / Q000033:anatomy & histology / Q000187:drug effects / Q000502:physiology*; D011388:Prolactin / Q000097:blood / Q000378:metabolism*; D051381:Rats; D017208:Rats, Wistar; D012016:Reference Values; D013004:Somatostatin / Q000031:analogs & derivatives*
chemical_list: D003692:Delayed-Action Preparations; D010456:Peptides, Cyclic; C060347:lanreotide; D004958:Estradiol; D013004:Somatostatin; D011388:Prolactin; D015282:Octreotide